Multiresistant tuberculosis;La Tuberculose multirésistante

Revue de Medecine Interne

Volumn 30, Issue SUPPL. 4, 2009, Pages

  Benfenatki, N ^a  

^a établissement public hospitalier de Rouiba   (Algeria)

Author keywords

Multiresistant tuberculosis; Struggle against tuberculosis; World health organization

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; OXAZOLIDINONE DERIVATIVE; PNU 100480; PYRAZINAMIDE; QUINOLONE; QUINOLONE DERIVATIVE; RBX 8700; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL STRAIN; BACTERIUM MUTANT; CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; SOUTH AFRICA; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; COMMUNICABLE DISEASES, EMERGING; HUMANS; PRIMARY PREVENTION; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 70849110711     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2009.09.016     Document Type: Article

References (36)

1. Migliori G.B., Fattorini L., Vaccarino P., et al. (Italian Multicentre Study of resistance to Anti-tuberculosis drugs) Study Group: Prevalence of resistance to anti-tuberculosis drugs: results of the 1998/99 national survey in Italy. Int J Tuberc Lung Dis 6 (2002) 32-38
2. Nelson L.J., Schaf H.S., Ozere I., Del Castillo H., PanovaL, Bamber V., et al. Multidrug -resistant tuberculosis in children:185 cases from 4 countries. Am J Resp Crit Med 169 (2004) A260
3. ATSCDCIDSA. Official joint statement on treatment of tuberculosis. Am J Respir Crit Care Med 167 (2003) 603-621
4. Iseman M.D. Treatment of multidrug-resistant tuberculosis. N Engl j Med 329 (1993) 784-791
5. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs worldwide 2000-2004. MMWR Morb Mortal Wkly Rep 2006;55:301-5.
6. Kipp W. Tuberculosis in the Eastern European countries and the former USSR. Heath Manage Forum 14 (2001) 54-59
7. Pablos-Mendez A., Raviglione M.C., Laszlo A., et al. Global surveillance for anti-tuberculosis drug resistance, 1994-1997. N Engl J Med 338 (1998) 1641-1649
8. Espinal M.A., Laszlo A., Simonsen L., et al. Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-tuberculosis Drug Resistance Surveillance. N Engl Med 344 (2001) 1294-1303
9. Kruuner A., Danilovitsh M., Pehme L., Laisaar T., Hoffner S.R., and Katila M.L. Tuberculosis as an occupational hazard for health care workers in Estonia. Int J Tubberc Lung Dis 5 (2001) 170-176
10. Becerra M.C., Bayona J., Freeman J., Farmer P.E., and Kim J.Y. Redefining MDR-TB transmission "hot spots". Int J Tuberc Lung Dis 4 (2000) 387-394
11. Dye C., Espinal M.A., Watt C.J., Mbiaga C., and Williams B.G. Worldwide incidence of multidrug-resistant tuberculosis. J infect Dis 185 (2002) 1197-1202
12. Crofton J, Chaulet P, Maher D. Guidelines for the management of drug resistant tuberculosis. World Health Organization; 1997 ed WHO/TB/96.210.
13. Frieden T.R., Sterling T., Pablos-Mendez A., Kilburn J.O., Cauthen G.M., and Dooley S.W. The emergence of drug-resistant tuberculosis i New York City. N Engl J Med 328 (1993) 521-526
14. Kimerling M.E. The Russian equation: an evolving paradigm in tuberculosis control. Int J Tuberc Lung Dis 4 (2000) S160
15. Beck-Sague C., Dooley S.W., Hutton M.D., Otten J., Breeden A., Crawford J.T., et al. Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIV -infected patients. JAMA 268 (1992) 1280-1286
16. Fischl M.A., Uttamchandani R.B., Daikos G.L., Poblete R.B., Moreno J.N., Reyes R.R., et al. An outbreak of tuberculosis caused by multiple -drug-resistant tubercle bacilli among patients with HIV infection. Ann Inter Med 117 (1992) 177-183
17. Bifani P.J., Plikaytis B.B., Kapur V., Stockbauer K., Pan X., Lutfey M.L., et al. Origin and interstate spread of a New York City multidrug resistant Mycobacterium tuberculosis clone family. JAMA 275 (1996) 452-457
18. Coronado V.G., Beck-Sague C.M., Hutton M.D., Davis B.J., Nicholas P., Villareal C., et al. Transmission of multidrug-resistant Mycobacterium tuberculosis among persons with human immunodeficiency virus infection in an urban hospital: epidemiologic and restriction fragment length polymorphism analysis. J Infect Dis 168 (1993) 1052-1055
19. Maloney S.A., Pearson M.L., Gordon M.T., Del Castillo R., Boyle J.F., and Jarvis W.R. Efficacy of Control Measures in Preventing Nosocomial Transmission of Multidrug-Resistant Tuberculosis to Patients and Health Care Workers. Ann Inter Med 122 (1995) 90-95
20. Dye C., and Williams B.G. Criteria for the control of drug-resistant tuberculosis. PNAS 97 (2000) 8180-8185
21. Farmer P., and Kim J.Y. Community based approaches to the control of multidrug resistant tubercuculosis: introducing "DOTS plus". BMJ 17 (1998) 671-674
22. Horsburgh C.R. The global problem of multidrug-resistant tuberculosis. JAMA 283 (2000) 2575-2576
23. World Health Organization. Global tuberculosis control. WHO report 2001, Geneva, Switzerland. WHO/CDS/TB/2001/287.
24. Espinal M.A., Kim S.J., Suarez P.G., Kam K.M., et al. Standard Short-course chemotherapy for drug-resistant tuberculosis. JAMA 283 (2000) 2437-2445
25. Espinal M.A., Kim S.J., Suarez P.G., Kam K.M., Khomenko A.G., Migliori G.B., et al. Standard short-course chemotherapy for drug-resistant tuberculosis. JAMA 283 (2000) 2537-2545
26. Geerligs W.A., Van Altena R., De Lange W.C.M., Van Soolingen D., and Van der Werft T.S. Mutidrug-resistant tuberculosis: long-term treatment outcomein the Netherlands. Int J Tuberc Lung Dis 4 (2000) 758-764
27. Yew W.W., Chan C.K., Chau C.H., Tam C.M., Leung C.C., Wong P.G., et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 117 (2000) 744
28. Blanc F.X. Tuberculose : encore plus fort que la multirésistance. Rev Mal Respir 23 (2006) 15S86-115S
29. Chan E.D., Laurel V., Strand M.J., Chan J.F., Huynh M.L., and Iseman M.D. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit care Med 169 (2004) 1103-1109
30. Yew W.W., Chan C.K., Leung C.C., Chau C.H., Tam C.M., Wong P.C., et al. Comparative roles of levofloxacine and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 124 (2003) 1476-1481
31. Kennedy N., Berger L., Curram J., Fox R., GurmannJ, Kisyombe G.M., et al. Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Clin Infect Dis 22 (1996) 827-833
32. Tyagi S., Nuermberger E., Yoshimatsu T., Williams K., Rosenthal L., Lounis N., et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 49 (2005) 2289-2293
33. Lenaerts A.J., Gruppo V., Marietta K.S., Johnson C.M., Driscoll D.K., Tompkins N.M., et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 49 (2005) 2294-2301
34. Drobniewski F., Eltringham I., Graham C., Magee J.G., Smith E.G., and Watt B. A national study of clinical and laboratory factors affecting the survival of patients with multiple drug resistant tuberculosis in the UK. Thorax 57 (2002) 810-816
35. Johnson B.J., Bekker L.G., Rickman R., Brown S., Lesser M., Ress S., et al. rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo. Tubercul Lung Dis 78 (1997) 195-203
36. Van Rie A., Warren R., Mshanga I., Jordaan A.M., Van Der Spuy G.D., Richardson M., et al. Analysis for a limited number of gene codons can predict drug resistance of Mycobacterium tuberculosis in a high-incidence community. J Clin Microbiol 39 (2001) 636-641